GUIDED THERAPEUTICS INC Annual Report - How They Did This Year

I’ve put together this guide to help you understand how Guided Therapeutics performed this year. My goal is to cut through the corporate jargon so you can decide if this company fits your investment goals.

1. What does this company do?

Guided Therapeutics is a medical technology company focused on light-based cervical cancer detection. Their primary product, the LuViva Advanced Cervical Scan, is a non-invasive device that scans the cervix to provide an immediate, objective result. This technology is designed to bypass the slow, subjective lab work required by traditional Pap smears.

They target two specific markets:

• The Developing World: Where a lack of laboratory infrastructure makes traditional screening difficult and expensive.
• The Developed World: They position LuViva as a "triage" tool to provide immediate clarity when Pap smears are inconclusive, helping doctors avoid unnecessary, invasive biopsies.

2. Financial performance: The "Survival Mode" Reality

The company’s finances remain in a precarious state. For the year ending December 31, 2025, they generated approximately $0.6 million in revenue, primarily from the sale of disposable scanning tips. However, operating costs—including research and administration—significantly exceeded this revenue, resulting in a $3.2 million loss for the year.

As of March 2026, there are roughly 96.35 million shares outstanding. To fund operations, the company frequently issues a mix of debt and preferred stock. These instruments often allow lenders to convert debt into common stock at a discount. For investors, this creates a dilution risk: as the company issues new shares to satisfy debt obligations, your percentage of ownership in the company is reduced.

3. Major wins and challenges

• The Debt Treadmill: The company is currently weighed down by high-interest, short-term debt. They often utilize financing arrangements that convert into stock at variable prices. This forces the company to issue new shares to pay off old debt, often at prices below the current market value, which can exert downward pressure on the stock price.
• Sustainability: The company is not yet self-sustaining. With less than $0.5 million in cash on hand and a monthly burn rate of $250,000 to $300,000, auditors have issued a "going concern" warning. This means the company must successfully raise new capital every few months just to maintain operations.

4. Key risks

The primary risk is liquidity. The company relies entirely on raising money through private investors or new debt to stay afloat. If they are unable to secure additional funding, they will be unable to cover payroll or vendor costs, which could force a shutdown.

Additionally, they face regulatory and adoption hurdles. Even with sufficient funding, LuViva requires ongoing international approvals. Furthermore, the company must convince medical providers to integrate the device into their standard workflows. If doctors do not adopt the technology, the company will struggle to reach the sales volume necessary to break even. Finally, the large volume of convertible notes creates a "stock overhang" that can suppress the share price.

5. Future outlook

The company’s immediate priority is stabilizing its balance sheet by moving away from high-interest, short-term debt. Their long-term survival depends on a "scale-up" strategy: increasing the number of LuViva devices installed to drive recurring sales of scanning tips. Until they can generate more revenue than they spend, they will continue to rely on external capital, leaving shareholders vulnerable to further dilution and significant price volatility.

Investor Takeaway: This is a high-risk, speculative investment. The company is currently in a "survival" phase, meaning their ability to stay in business depends on constant fundraising. Before considering an investment, weigh the potential of their technology against the reality of their ongoing financial losses and the likelihood of future share dilution.